SCHEMBL2067685

SCHEMBL2067685

C/C(=N\N)c1ccc(C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FURIN P09958 1/20 0.44
ALDH1A1 P00352 5/20 0.44
LMNA P02545 2/20 0.44
CES2 O00748 2/20 0.44
CES1 P23141 2/20 0.44
TDP1 Q9NUW8 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
STAT3 P40763 1/20 0.43
STAT1 P42224 1/20 0.43
RAB9A P51151 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.41
HIF1A Q16665 1/20 0.41
ACHE P22303 1/20 0.40
PKM P14618 2/20 0.39
HTT P42858 2/20 0.39
ATM Q13315 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846692 1.00 FURIN (0.44) FURINALDH1A1LMNACES2CES1
SCHEMBL15784371 0.82 CYP1A2 (0.33) FURINALDH1A1LMNACES2CES1
SCHEMBL2704783 0.80 MEN1 (0.47) FURINALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL15053148 0.80 CYP19A1 (0.50) FURINALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL10802341 0.79 FURIN (0.61) FURINALDH1A1LMNACES2CES1
SCHEMBL23837603 0.78 LMNA (0.53) FURINALDH1A1LMNACES2CES1
SCHEMBL15053824 0.78 LMNA (0.53) FURINALDH1A1LMNACES2CES1
SCHEMBL5415127 0.78 MAPT (0.50) FURINALDH1A1CES2CES1TDP1
SCHEMBL6734907 0.78 LMNA (0.61) FURINALDH1A1LMNACES2CES1
SCHEMBL6053302 0.78 MAPT (0.50) FURINALDH1A1CES2CES1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199920-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2015-12-01 US claimed
US-8492434-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES INC. (US) 2013-07-23 US claimed
US-20130165493-A1 Antiviral Drugs for Treatment of Arenavirus Infection Siga Technologies, Inc, (US) 2013-06-27 US claimed
US-8492434-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES INC. (US) 2013-07-23 US disclosed
US-20130165493-A1 Antiviral Drugs for Treatment of Arenavirus Infection Siga Technologies, Inc, (US) 2013-06-27 US disclosed
US-8148428-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2012-04-03 US disclosed
US-20090036513-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES, INC. (US) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165493-A1 Antiviral Drugs for Treatment of Arenavirus Infection GK, ZC3HAV1, GALK1 FURIN 1660/4885ALDH1A1 4066/4885LMNA 2765/4885
US-20090036513-A1 Antiviral Drugs for Treatment of Arenavirus Infection GK, ZC3HAV1, GALK1 FURIN 1660/4885ALDH1A1 4066/4885LMNA 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.